1
|
Prates JLB, Lopes JR, Chin CM, Ferreira EI, Dos Santos JL, Scarim CB. Discovery of Novel Inhibitors of Cruzain Cysteine Protease of Trypanosoma cruzi. Curr Med Chem 2024; 31:2285-2308. [PMID: 37888814 DOI: 10.2174/0109298673254864230921090519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Revised: 07/11/2023] [Accepted: 08/15/2023] [Indexed: 10/28/2023]
Abstract
Chagas disease (CD) is a parasitic disease endemic in several developing countries. According to the World Health Organization, approximately 6-8 million people worldwide are inflicted by CD. The scarcity of new drugs, mainly for the chronic phase, is the main reason for treatment limitation in CD. Therefore, there is an urgent need to discover new targets for which new therapeutical agents could be developed. Cruzain cysteine protease (CCP) is a promising alternative because this enzyme exhibits pleiotropic effects by acting as a virulence factor, modulating host immune cells, and interacting with host cells. This systematic review was conducted to discover new compounds that act as cruzain inhibitors, and their effects in vitro were studied through enzymatic assays and molecular docking. Additionally, the advances and perspectives of these inhibitors are discussed. These findings are expected to contribute to medicinal chemistry in view of the design of new, safe, and efficacious inhibitors against Trypanosoma cruzi CCP detected in the last decade (2013-2022) to provide scaffolds for further optimization, aiming toward the discovery of new drugs.
Collapse
Affiliation(s)
- João Lucas Bruno Prates
- Department of Drugs and Medicine, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil
- Chemistry Institute Araraquara, São Paulo State University (UNESP), SP, Brazil
| | - Juliana Romano Lopes
- Department of Drugs and Medicine, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil
| | - Chung Man Chin
- Department of Drugs and Medicine, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil
- Union of the Colleges of the Great Lakes (UNILAGO), School of Medicine, Advanced Research Center in Medicine, São José do Rio Preto, SP, Brazil
| | - Elizabeth Igne Ferreira
- LAPEN-Laboratory of Design and Synthesis of Chemotherapeutic Agents Potentially Active on Neglected Diseases, Department of Pharmacy, School of Pharmaceutical Sciences, University of São Paulo (USP), São Paulo, SP, Brazil
| | - Jean Leandro Dos Santos
- Department of Drugs and Medicine, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil
- Chemistry Institute Araraquara, São Paulo State University (UNESP), SP, Brazil
| | - Cauê Benito Scarim
- Department of Drugs and Medicine, School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara, SP, Brazil
| |
Collapse
|
2
|
Giroud M, Kuhn B, Haap W. Drug Discovery Efforts to Identify Novel Treatments for Neglected Tropical Diseases - Cysteine Protease Inhibitors. Curr Med Chem 2024; 31:2170-2194. [PMID: 37916489 DOI: 10.2174/0109298673249097231017051733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 06/19/2023] [Accepted: 09/14/2023] [Indexed: 11/03/2023]
Abstract
BACKGROUND Neglected tropical diseases are a severe burden for mankind, affecting an increasing number of people around the globe. Many of those diseases are caused by protozoan parasites in which cysteine proteases play a key role in the parasite's pathogenesis. OBJECTIVE In this review article, we summarize the drug discovery efforts of the research community from 2017 - 2022 with a special focus on the optimization of small molecule cysteine protease inhibitors in terms of selectivity profiles or drug-like properties as well as in vivo studies. The cysteine proteases evaluated by this methodology include Cathepsin B1 from Schistosoma mansoni, papain, cruzain, falcipain, and rhodesain. METHODS Exhaustive literature searches were performed using the keywords "Cysteine Proteases" and "Neglected Tropical Diseases" including the years 2017 - 2022. Overall, approximately 3'000 scientific papers were retrieved, which were filtered using specific keywords enabling the focus on drug discovery efforts. RESULTS AND CONCLUSION Potent and selective cysteine protease inhibitors to treat neglected tropical diseases were identified, which progressed to pharmacokinetic and in vivo efficacy studies. As far as the authors are aware of, none of those inhibitors reached the stage of active clinical development. Either the inhibitor's potency or pharmacokinetic properties or safety profile or a combination thereof prevented further development of the compounds. More efforts with particular emphasis on optimizing pharmacokinetic and safety properties are needed, potentially by collaborations of academic and industrial research groups with complementary expertise. Furthermore, new warheads reacting with the catalytic cysteine should be exploited to advance the research field in order to make a meaningful impact on society.
Collapse
Affiliation(s)
- Maude Giroud
- Pharma Research and Early Development pRED, Roche Innovation Center Basel, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, CH-4070, Switzerland
| | - Bernd Kuhn
- Pharma Research and Early Development pRED, Roche Innovation Center Basel, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, CH-4070, Switzerland
| | - Wolfgang Haap
- Pharma Research and Early Development pRED, Roche Innovation Center Basel, Medicinal Chemistry, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel, CH-4070, Switzerland
| |
Collapse
|
3
|
Martins LC, de Oliveira RB, Lameira J, Ferreira RS. Experimental and Computational Study of Aryl-thiosemicarbazones Inhibiting Cruzain Reveals Reversible Inhibition and a Stepwise Mechanism. J Chem Inf Model 2023; 63:1506-1520. [PMID: 36802548 DOI: 10.1021/acs.jcim.2c01566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Trypanosoma cruzi is a parasite that infects about 6-7 million people worldwide, mostly in Latin America, causing Chagas disease. Cruzain, the main cysteine protease of T. cruzi, is a validated target for developing drug candidates for Chagas disease. Thiosemicarbazones are one of the most relevant warheads used in covalent inhibitors targeting cruzain. Despite its relevance, the mechanism of inhibition of cruzain by thiosemicarbazones is unknown. Here, we combined experiments and simulations to unveil the covalent inhibition mechanism of cruzain by a thiosemicarbazone-based inhibitor (compound 1). Additionally, we studied a semicarbazone (compound 2), which is structurally similar to compound 1 but does not inhibit cruzain. Assays confirmed the reversibility of inhibition by compound 1 and suggested a two-step mechanism of inhibition. The Ki was estimated to be 36.3 μM and Ki* to be 11.5 μM, suggesting the pre-covalent complex to be relevant for inhibition. Molecular dynamics simulations of compounds 1 and 2 with cruzain were used to propose putative binding modes for the ligands. One-dimensional (1D) quantum mechanics/molecular mechanics (QM/MM) potential of mean force (PMF) and gas-phase energies showed that the attack of Cys25-S- on the C═S or C═O bond yields a more stable intermediate than the attack on the C═N bond of the thiosemicarbazone/semicarbazone. Two-dimensional (2D) QM/MM PMF revealed a putative reaction mechanism for compound 1, involving the proton transfer to the ligand, followed by the Cys25-S- attack at C═S. The ΔG and energy barrier were estimated to be -1.4 and 11.7 kcal/mol, respectively. Overall, our results shed light on the inhibition mechanism of cruzain by thiosemicarbazones.
Collapse
Affiliation(s)
- Luan Carvalho Martins
- Molecular Modeling and Drug Design Laboratory, Institute for Biological Sciences, Federal University of Minas Gerais, 6627, Antônio Carlos Avenue, 31270-901 Belo Horizonte, MG, Brazil
| | - Renata Barbosa de Oliveira
- Pharmaceutical Products Department, Faculty of Pharmacy, Federal University of Minas Gerais, 6627, Antônio Carlos Avenue, 31270-901 Belo Horizonte, MG, Brazil
| | - Jerônimo Lameira
- Institute of Biological Sciences, Federal University of Pará, 66075-110 Belém, Pará, Brazil
| | - Rafaela Salgado Ferreira
- Molecular Modeling and Drug Design Laboratory, Institute for Biological Sciences, Federal University of Minas Gerais, 6627, Antônio Carlos Avenue, 31270-901 Belo Horizonte, MG, Brazil
| |
Collapse
|
4
|
Acylhydrazones and Their Biological Activity: A Review. MOLECULES (BASEL, SWITZERLAND) 2022; 27:molecules27248719. [PMID: 36557851 PMCID: PMC9783609 DOI: 10.3390/molecules27248719] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 12/02/2022] [Accepted: 12/07/2022] [Indexed: 12/13/2022]
Abstract
Due to the structure of acylhydrazones both by the pharmacophore -CO-NH-N= group and by the different substituents present in the molecules of compounds of this class, various pharmacological activities were reported, including antitumor, antimicrobial, antiviral, antiparasitic, anti-inflammatory, immunomodulatory, antiedematous, antiglaucomatous, antidiabetic, antioxidant, and actions on the central nervous system and on the cardiovascular system. This fragment is found in the structure of several drugs used in the therapy of some diseases that are at the top of public health problems, like microbial infections and cardiovascular diseases. Moreover, the acylhydrazone moiety is present in the structure of some compounds with possible applications in the treatment of other different pathologies, such as schizophrenia, Parkinson's disease, Alzheimer's disease, and Huntington's disease. Considering these aspects, we consider that a study of the literature data regarding the structural and biological properties of these compounds is useful.
Collapse
|
5
|
Nunes JA, Ferreira da Silva-Júnior E. Hybrid-Compounds Against Trypanosomiases. Curr Drug Targets 2022; 23:1319-1329. [PMID: 35579157 DOI: 10.2174/1389450123666220509202352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 03/11/2022] [Accepted: 03/22/2022] [Indexed: 01/25/2023]
Abstract
Neglected tropical diseases (NTDs) are a global public health problem associated with approximately 20 conditions. Among these, Chagas disease (CD), caused by Trypanosoma cruzi, and human African trypanosomiasis (HAT), caused by T. brucei gambiense or T. brucei rhodesiense, affect mainly the populations of the countries from the American continent and sub- Saharan Africa. Pharmacological therapies used for such illnesses are not yet fully effective. In this context, the search for new therapeutic alternatives against these diseases becomes necessary. A drug design tool, recently recognized for its effectiveness in obtaining ligands capable of modulating multiple targets for complex diseases, concerns molecular hybridization. Therefore, this review aims to demonstrate the importance of applying molecular hybridization in facing the challenges of developing prototypes as candidates for the treatment of parasitic diseases. Therefore, studies involving different chemical classes that investigated and used hybrid compounds in recent years were compiled in this work, such as thiazolidinones, naphthoquinones, quinolines, and others. Finally, this review covers several applications of the exploration of molecular hybridization as a potent strategy in the development of molecules potentially active against trypanosomiases, in order to provide information that can help in designing new drugs with trypanocidal activity.
Collapse
Affiliation(s)
- Jessica Alves Nunes
- Institute of Chemistry and Biotechnology, Federal University of Alagoas, 57072-970, Maceió, Brazil
| | - Edeildo Ferreira da Silva-Júnior
- Institute of Chemistry and Biotechnology, Federal University of Alagoas, 57072-970, Maceió, Brazil.,Institute of Pharmaceutical Sciences, Federal University of Alagoas, 57072-970, Maceió, Brazil
| |
Collapse
|
6
|
Martinho ACC, Resende DDM, Landin ES, Dit Lapierre TJWJ, Bernardes TCD, Martins LC, Ferreira RS, Murta SMF, de Oliveira Rezende Júnior C. Synthesis, Design, and Structure-Activity Relationship of a Benzenesulfonylpiperazine Series Against Trypanosoma Cruzi. ChemMedChem 2022; 17:e202200211. [PMID: 35993440 DOI: 10.1002/cmdc.202200211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 08/19/2022] [Indexed: 11/09/2022]
Abstract
Chagas disease is a neglected tropical disease, endemic in Latin America and caused by the protozoan parasite Trypanosoma cruzi . Available treatments show low cure efficacy during the chronic phase of the disease and cause a series of side effects, reinforcing the need to develop new drugs against Chagas disease. In this work, we describe the optimization of a trypanocidal hit compound recently reported in phenotypic HTS studies against Trypanosoma cruzi . A hit-to-lead process was initiated and a structure-activity relationship against Trypanosoma cruzi was obtained after the synthesis and biological evaluation of 22 new benzenesulfonylpiperazine derivatives. From this SAR study, we identified three compounds with a promising predicted ADMET profile and potency comparable to the reference drug benznidazole, which are candidates for further development towards therapies for Chagas disease.
Collapse
Affiliation(s)
| | - Daniela de Melo Resende
- Fundação Oswaldo Cruz Instituto René Rachou: Fundacao Oswaldo Cruz Instituto Rene Rachou, René Rachou Institute, BRAZIL
| | - Emanuelly Silva Landin
- Federal University of Uberlandia: Universidade Federal de Uberlandia, Chemistry Institute, BRAZIL
| | | | | | - Luan Carvalho Martins
- Federal University of Minas Gerais: Universidade Federal de Minas Gerais, Biochemistry and immunology, BRAZIL
| | - Rafaela Salgado Ferreira
- Federal University of Minas Gerais: Universidade Federal de Minas Gerais, Biochemistry and immunology, BRAZIL
| | - Silvane Maria Fonseca Murta
- Oswaldo Cruz Foundation Rene Rachou Institute: Fundacao Oswaldo Cruz Instituto Rene Rachou, René Rachou Institute, BRAZIL
| | | |
Collapse
|
7
|
4-Amino-3-(1-{[amino(3-methyl-2-oxido-1,2,5-oxadiazol-4-yl)methylene]hydrazinylidene}ethyl)-1,2,5-oxadiazole 2-Oxide. MOLBANK 2022. [DOI: 10.3390/m1425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Functionally substituted 1,2,5-oxadiazole 2-oxides (furoxans) are important pharmaceutical scaffolds used for the preparation of various pharmacologically active substances. Furoxans bearing hydrazone functionality are considered as promising drug candidates for the treatment of neglected diseases. However, pharmacologically oriented hydrazones derived from (furoxanyl)amidrazones and acetylfuroxans have remained unknown so far. In this communication, a simple method for the synthesis of 4-amino-3-(1-{[amino(3-methyl-2-oxido-1,2,5-oxadiazol-4-yl)methylene]hydrazinylidene}ethyl)-1,2,5-oxadiazole 2-oxide is described. The structure of the synthesized compound was established by elemental analysis, high-resolution mass spectrometry, 1H, 13C NMR and IR spectroscopy.
Collapse
|
8
|
Santos SS, Gonzaga RV, Scarim CB, Giarolla J, Primi MC, Chin CM, Ferreira EI. Drug/Lead Compound Hydroxymethylation as a Simple Approach to Enhance Pharmacodynamic and Pharmacokinetic Properties. Front Chem 2022; 9:734983. [PMID: 35237565 PMCID: PMC8883432 DOI: 10.3389/fchem.2021.734983] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2021] [Accepted: 10/20/2021] [Indexed: 11/17/2022] Open
Abstract
Hydroxymethylation is a simple chemical reaction, in which the introduction of the hydroxymethyl group can lead to physical–chemical property changes and offer several therapeutic advantages, contributing to the improved biological activity of drugs. There are many examples in the literature of the pharmaceutical, pharmacokinetic, and pharmacodynamic benefits, which the hydroxymethyl group can confer to drugs, prodrugs, drug metabolites, and other therapeutic compounds. It is worth noting that this group can enhance the drug’s interaction with the active site, and it can be employed as an intermediary in synthesizing other therapeutic agents. In addition, the hydroxymethyl derivative can result in more active compounds than the parent drug as well as increase the water solubility of poorly soluble drugs. Taking this into consideration, this review aims to discuss different applications of hydroxymethyl derived from biological agents and its influence on the pharmacological effects of drugs, prodrugs, active metabolites, and compounds of natural origin. Finally, we report a successful compound synthesized by our research group and used for the treatment of neglected diseases, which is created from the hydroxymethylation of its parent drug.
Collapse
Affiliation(s)
- Soraya S. Santos
- Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Em Doenças Negligenciadas (LAPEN), Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo – USP, São Paulo, Brazil
| | - Rodrigo V. Gonzaga
- Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Em Doenças Negligenciadas (LAPEN), Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo – USP, São Paulo, Brazil
| | - Cauê B. Scarim
- Laboratório de Pesquisa e Desenvolvimento de Fármacos (LAPDESF), Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Universidade Estadual de São Paulo “Júlio de Mesquita Filho” (UNESP), Araraquara, Brazil
| | - Jeanine Giarolla
- Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Em Doenças Negligenciadas (LAPEN), Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo – USP, São Paulo, Brazil
| | | | - Chung M. Chin
- Laboratório de Pesquisa e Desenvolvimento de Fármacos (LAPDESF), Departamento de Fármacos e Medicamentos, Faculdade de Ciências Farmacêuticas, Universidade Estadual de São Paulo “Júlio de Mesquita Filho” (UNESP), Araraquara, Brazil
- Centro de Pesquisa Avançada Em Medicina (CEPAM), Faculdade de Medicina, União Das Faculdades Dos Grande Lagos (UNILAGO), São José Do Rio Preto, Brazil
| | - Elizabeth I. Ferreira
- Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos Em Doenças Negligenciadas (LAPEN), Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo – USP, São Paulo, Brazil
- *Correspondence: Elizabeth I. Ferreira,
| |
Collapse
|
9
|
Pauli I, Rezende CDO, Slafer BW, Dessoy MA, de Souza ML, Ferreira LLG, Adjanohun ALM, Ferreira RS, Magalhães LG, Krogh R, Michelan-Duarte S, Del Pintor RV, da Silva FBR, Cruz FC, Dias LC, Andricopulo AD. Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics. Front Pharmacol 2022; 12:774069. [PMID: 35069198 PMCID: PMC8767159 DOI: 10.3389/fphar.2021.774069] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2021] [Accepted: 11/22/2021] [Indexed: 12/20/2022] Open
Abstract
Cruzain, the main cysteine protease of Trypanosoma cruzi, plays key roles in all stages of the parasite's life cycle, including nutrition acquisition, differentiation, evasion of the host immune system, and invasion of host cells. Thus, inhibition of this validated target may lead to the development of novel drugs for the treatment of Chagas disease. In this study, a multiparameter optimization (MPO) approach, molecular modeling, and structure-activity relationships (SARs) were employed for the identification of new benzimidazole derivatives as potent competitive inhibitors of cruzain with trypanocidal activity and suitable pharmacokinetics. Extensive pharmacokinetic studies enabled the identification of metabolically stable and permeable compounds with high selectivity indices. CYP3A4 was found to be involved in the main metabolic pathway, and the identification of metabolic soft spots provided insights into molecular optimization. Compound 28, which showed a promising trade-off between pharmacodynamics and pharmacokinetics, caused no acute toxicity and reduced parasite burden both in vitro and in vivo.
Collapse
Affiliation(s)
- Ivani Pauli
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | - Celso de O Rezende
- Instituto de Química, Universidade Estadual de Campinas, Campinas, Brazil
| | - Brian W Slafer
- Instituto de Química, Universidade Estadual de Campinas, Campinas, Brazil
| | - Marco A Dessoy
- Instituto de Química, Universidade Estadual de Campinas, Campinas, Brazil
| | - Mariana L de Souza
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | - Leonardo L G Ferreira
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | - Abraham L M Adjanohun
- Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Rafaela S Ferreira
- Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Luma G Magalhães
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | - Renata Krogh
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | - Simone Michelan-Duarte
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| | | | | | - Fabio C Cruz
- Departamento de Farmacologia, Universidade Federal de São Paulo, São Paulo, Brazil
| | - Luiz C Dias
- Instituto de Química, Universidade Estadual de Campinas, Campinas, Brazil
| | - Adriano D Andricopulo
- Laboratório de Química Medicinal e Computacional, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, Brazil
| |
Collapse
|
10
|
Fershtat LL, Zhilin ES. Recent Advances in the Synthesis and Biomedical Applications of Heterocyclic NO-Donors. Molecules 2021; 26:5705. [PMID: 34577175 PMCID: PMC8470015 DOI: 10.3390/molecules26185705] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 09/16/2021] [Accepted: 09/18/2021] [Indexed: 11/16/2022] Open
Abstract
Nitric oxide (NO) is a key signaling molecule that acts in various physiological processes such as cellular metabolism, vasodilation and transmission of nerve impulses. A wide number of vascular diseases as well as various immune and neurodegenerative disorders were found to be directly associated with a disruption of NO production in living organisms. These issues justify a constant search of novel NO-donors with improved pharmacokinetic profiles and prolonged action. In a series of known structural classes capable of NO release, heterocyclic NO-donors are of special importance due to their increased hydrolytic stability and low toxicity. It is no wonder that synthetic and biochemical investigations of heterocyclic NO-donors have emerged significantly in recent years. In this review, we summarized recent advances in the synthesis, reactivity and biomedical applications of promising heterocyclic NO-donors (furoxans, sydnone imines, pyridazine dioxides, azasydnones). The synthetic potential of each heterocyclic system along with biochemical mechanisms of action are emphasized.
Collapse
Affiliation(s)
- Leonid L. Fershtat
- Laboratory of Nitrogen Compounds, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, 119991 Moscow, Russia;
| | | |
Collapse
|
11
|
Yepes AF, Quintero‐Saumeth J, Cardona‐Galeano W. Biologically Active Quinoline‐Hydrazone Conjugates as Potential
Trypanosoma cruzi
DHFR‐TS Inhibitors: Docking, Molecular Dynamics, MM/PBSA and Drug‐Likeness Studies. ChemistrySelect 2021. [DOI: 10.1002/slct.202100238] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Andrés F. Yepes
- Chemistry of Colombian Plants, Institute of Chemistry, Faculty of Exact and Natural Sciences University of Antioquia-UdeA, Calle 70 No. 52-21, A.A 1226 Medellín Colombia
| | - Jorge Quintero‐Saumeth
- University of Pamplona Faculty of Basic Sciences, Pamplona, Colombia, Km 1 Vía Bucaramanga Ciudad Universitaria Pamplona Colombia
| | - Wilson Cardona‐Galeano
- Chemistry of Colombian Plants, Institute of Chemistry, Faculty of Exact and Natural Sciences University of Antioquia-UdeA, Calle 70 No. 52-21, A.A 1226 Medellín Colombia
| |
Collapse
|
12
|
Rosas-Jimenez JG, Garcia-Revilla MA, Madariaga-Mazon A, Martinez-Mayorga K. Predictive Global Models of Cruzain Inhibitors with Large Chemical Coverage. ACS OMEGA 2021; 6:6722-6735. [PMID: 33748586 PMCID: PMC7970485 DOI: 10.1021/acsomega.0c05645] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Accepted: 02/11/2021] [Indexed: 06/12/2023]
Abstract
Chagas disease affects 8-11 million people worldwide, most of them living in Latin America. Moreover, migratory phenomena have spread the infection beyond endemic areas. Efforts for the development of new pharmacological therapies are paramount as the pharmacological profile of the two marketed drugs currently available, nifurtimox and benznidazole, needs to be improved. Cruzain, a parasitic cysteine protease, is one of the most attractive biological targets due to its roles in parasite survival and immune evasion. In this work, we compiled and curated a database of diverse cruzain inhibitors previously reported in the literature. From this data set, quantitative structure-activity relationship (QSAR) models for the prediction of their pIC50 values were generated using k-nearest neighbors and random forest algorithms. Local and global models were calculated and compared. The statistical parameters for internal and external validation indicate a significant predictability, with q loo 2 values around 0.66 and 0.61 and external R 2 coefficients of 0.725 and 0.766. The applicability domain is quantitatively defined, according to QSAR good practices, using the leverage and similarity methods. The models described in this work are readily available in a Python script for the discovery of novel cruzain inhibitors.
Collapse
Affiliation(s)
- Jose Guadalupe Rosas-Jimenez
- Division
de Ciencias Naturales y Exactas, Universidad
de Guanajuato, Guanajuato 36050, Mexico
- Instituto
de Quimica, Universidad Nacional Autonoma
de Mexico, Mexico
City 04510, Mexico
| | - Marco A. Garcia-Revilla
- Division
de Ciencias Naturales y Exactas, Universidad
de Guanajuato, Guanajuato 36050, Mexico
| | | | | |
Collapse
|
13
|
Sanz CG, Dias KA, Bacil RP, Serafim RA, Andrade LH, Ferreira EI, Serrano SH. Electrochemical characterization of para- and meta-nitro substituents in aqueous media of new antichagasic pharmaceutical leaders. Electrochim Acta 2021. [DOI: 10.1016/j.electacta.2020.137582] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Bystrov DM, Ananyev IV, Fershtat LL, Makhova NN. Direct Synthesis of N-(1,2,5-Oxadiazolyl)hydrazones through a Diazotization/Reduction/Condensation Cascade. J Org Chem 2020; 85:15466-15475. [PMID: 33185453 DOI: 10.1021/acs.joc.0c02243] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A straightforward synthesis of a series of previously unknown N-(1,2,5-oxadiazolyl)hydrazones through the diazotization/reduction/condensation cascade of amino-1,2,5-oxadiazoles was accomplished. The described protocol was suitable for a wide array of target hydrazones, which were prepared in good to high yields under smooth reaction conditions with very good functional group tolerance. Importantly, the presented approach unveils a direct route to in situ generation of previously inaccessible (1,2,5-oxadiazolyl)hydrazines. In addition, a first example of the ionic structure incorporating a protonated hydrazone motif linked to the 1,2,5-oxadiazole 2-oxide subunit was synthesized, indicating the stability of prepared compounds toward acid-promoted hydrolysis. Overall, this method provides a direct access to the isosteric analogues of drug candidates for treatment of various neglected diseases, thus enabling their potential application in medicinal chemistry and drug design.
Collapse
Affiliation(s)
- Dmitry M Bystrov
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, Moscow 119991, Russia
| | - Ivan V Ananyev
- A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Vavilova Str., 28, Moscow 119991, Russia.,Plekhanov Russian University of Economics, Stremyanny Per. 36, Moscow 117997, Russia
| | - Leonid L Fershtat
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, Moscow 119991, Russia
| | - Nina N Makhova
- N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prosp., 47, Moscow 119991, Russia
| |
Collapse
|
15
|
Synthesis and biological evaluation in vitro and in silico of N-propionyl-N'-benzeneacylhydrazone derivatives as cruzain inhibitors of Trypanosoma cruzi. Mol Divers 2020; 26:39-50. [PMID: 33216257 DOI: 10.1007/s11030-020-10156-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 11/04/2020] [Indexed: 01/15/2023]
Abstract
An N-acylhydrazone scaffold has been used to develop new drugs with diverse biological activities, including trypanocidal activity against different strains of Trypanosoma cruzi. However, their mechanism of action is not clear, although in T. cruzi it has been suggested that the enzyme cruzain is involved. The aim in this work was to obtain new N-propionyl-N'-benzeneacylhydrazone derivatives as potential anti-T. cruzi agents and elucidate their potential mechanism of action by a molecular docking analysis and effects on the expression of the cruzain gene. Compounds 9 and 12 were the most active agents against epimastigotes and compound 5 showed better activity than benznidazole in T. cruzi blood trypomastigotes. Additionally, compounds 9 and 12 significantly increase the expression of the cruzain gene. In summary, the in silico and in vitro data presented herein suggest that compound 9 is a cruzain inhibitor.
Collapse
|
16
|
Zhilin ES, Polkovnichenko MS, Ananyev IV, Fershtat LL, Makhova NN. Novel Arylazo‐1,2,5‐oxadiazole Photoswitches: Synthesis, Photoisomerization and Nitric Oxide Releasing Properties. CHEMPHOTOCHEM 2020. [DOI: 10.1002/cptc.202000157] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Egor S. Zhilin
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences Moskva 119991 Leninsky Prospect, 47 Moscow Russia
| | - Michael S. Polkovnichenko
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences Moskva 119991 Leninsky Prospect, 47 Moscow Russia
- Department of Chemistry M. V. Lomonosov Moscow State University Moskva 119991 Leninskie Gory 1–3 Moscow Russia
| | - Ivan V. Ananyev
- A. N. Nesmeyanov Institute of Organoelement Compounds Russian Academy of Sciences Moskva 119991 Vavilova str., 28 Moscow Russia
| | - Leonid L. Fershtat
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences Moskva 119991 Leninsky Prospect, 47 Moscow Russia
| | - Nina N. Makhova
- N.D. Zelinsky Institute of Organic Chemistry Russian Academy of Sciences Moskva 119991 Leninsky Prospect, 47 Moscow Russia
| |
Collapse
|
17
|
Teslenko FE, Churakov AI, Larin AA, Ananyev IV, Fershtat LL, Makhova NN. Route to 1,2,4- and 1,2,5-oxadiazole ring assemblies via a one-pot condensation/oxidation protocol. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.151678] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
18
|
da Silva Lima CH, de Araujo Vanelis Soares JC, de Sousa Ribeiro JL, Muri EMF, de Albuquerque S, Dias LRS. Anti-Trypanosoma cruzi Activity and Molecular Docking Studies of 1Hpyrazolo[ 3, 4-b]pyridine Derivatives. LETT DRUG DES DISCOV 2020. [DOI: 10.2174/1570180816666190305141733] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Untargeted studies led to the development of some pyrazolopyridine
derivatives for the antiparasitic profile, particularly the derivatives containing the structural
carbohydrazide subunit. In this work, we proceeded in the biological screening of 27 N’- (substitutedphenylmethylene)-
4-carbohydrazide-3-methyl-1-phenyl-1H-pyrazolo[3, 4-b]pyridine derivatives against
T. cruzi as well as the cytotoxic evaluation. To obtain more information about the trypanocidal
activity of this class of compounds, we carried out molecular docking simulations to get an insight
into putative targets in T. cruzi.
Methods:
The assays were evaluated against both trypomastigote and amastigote forms of T. cruzi
and cytotoxicity assays on LLCMK2 cells. The predominant conformational compounds were
analyzed and molecular docking simulations performed.
Results:
The results from trypanocidal activity screening of this series showed that just the
compounds with phenyl group at C-6 position exhibited activity and the N’-4-hydroxyphenylmethylene
derivative presented the best profile against both trypomastigote and amastigote
forms of T. cruzi. Docking simulation results showed that this compound has a binding affinity with
both CYP51 and cruzain targets of T. cruzi.
Conclusion:
Our results indicate that the hydroxyl substituent at the N’-substituted-phenylmethylene
moiety and the phenyl ring at C-6 of 1H-pyrazolo[3,4-b]pyridine system are relevant for the
trypanocidal activity of this class of compounds. Also, docking simulations showed that activity
presented can be related to more than one target of the parasite.
Collapse
Affiliation(s)
- Camilo Henrique da Silva Lima
- Laboratório de Quimica Medicinal, Universidade Federal Fluminense, Faculdade de Farmacia, Niteroi, Rio de Janeiro, Brazil
| | | | - Joana Lucius de Sousa Ribeiro
- Laboratório de Quimica Medicinal, Universidade Federal Fluminense, Faculdade de Farmacia, Niteroi, Rio de Janeiro, Brazil
| | - Estela Maris Freitas Muri
- Laboratório de Quimica Medicinal, Universidade Federal Fluminense, Faculdade de Farmacia, Niteroi, Rio de Janeiro, Brazil
| | - Sérgio de Albuquerque
- Universidade de Sao Paulo, Departamento de Analises Clinicas, Toxicologicas e Bromatologicas, Av. do Cafe s/n, Ribeirao Preto, SP, 14040-903, Brazil
| | - Luiza Rosaria Sousa Dias
- Laboratório de Quimica Medicinal, Universidade Federal Fluminense, Faculdade de Farmacia, Niteroi, Rio de Janeiro, Brazil
| |
Collapse
|
19
|
Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease. Med Chem Res 2019. [DOI: 10.1007/s00044-019-02453-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
20
|
Antiparasitic effect of (-)-α-bisabolol against Trypanosoma cruzi Y strain forms. Diagn Microbiol Infect Dis 2019; 95:114860. [PMID: 31353066 DOI: 10.1016/j.diagmicrobio.2019.06.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2018] [Revised: 05/20/2019] [Accepted: 06/18/2019] [Indexed: 12/22/2022]
Abstract
Chagas disease is caused by Trypanosoma cruzi and affects about 7 million people worldwide. Benznidazole and nifurtimox have low efficacy and high toxicity. The present study was designed to identify the trypanocidal effect of (-)-α-Bisabolol (BIS) and investigate its mechanism. Epimastigotes and trypomastigotes were cultured with BIS and the viable cells were counted. BIS antiamastigote effect was evaluated using infected LLC-MK2 cells. MTT assay was performed to evaluate BIS cytotoxicity. Growth recovery was assessed to evaluate BIS effect after short times of exposure. BIS mechanism was investigated through flow cytometry, with 7-AAD and Annexin V-PE. DCFH-DA, rhodamine 123 (Rho123) and acridine orange (AO). Finally, enzymatic and computational assays were performed to identify BIS interaction with T. cruzi GAPDH (tcGAPDH). BIS showed an inhibitory effect on epimastigotes after all tested periods, as well on trypomastigotes. It caused cytotoxicity on LLC-MK2 cells at higher concentrations, with selectivity index (SeI) = 26.5. After treatment, infected cells showed a decrease in infected cells, the number of amastigotes per infected cell and the survival index (SuI). Growth recovery demonstrated that BIS effect causes rapid death of T. cruzi. Flow cytometry showed that BIS biological effect is associated with apoptosis induction, increase in cytoplasmic ROS and mitochondrial transmembrane potential, while reservosome swelling was observed at a late stage. Also, BIS action mechanism may be associated to tcGAPDH inhibition. Altogether, the results demonstrate that BIS causes cell death in Trypanosoma cruzi Y strain forms, with the involvement of apoptosis and oxidative stress and enzymatic inhibition.
Collapse
|
21
|
Zhilin ES, Fershtat LL, Bystrov DM, Kulikov AS, Dmitrienko AO, Ananyev IV, Makhova NN. Renaissance of 1,2,5-Oxadiazolyl Diazonium Salts: Synthesis and Reactivity. European J Org Chem 2019. [DOI: 10.1002/ejoc.201900622] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Egor S. Zhilin
- N.D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prospect, 47 119991 Moscow Russia
| | - Leonid L. Fershtat
- N.D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prospect, 47 119991 Moscow Russia
| | - Dmitry M. Bystrov
- N.D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prospect, 47 119991 Moscow Russia
| | - Alexander S. Kulikov
- N.D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prospect, 47 119991 Moscow Russia
| | - Artem O. Dmitrienko
- A. N. Nesmeyanov Institute of Organoelement Compounds; Russian Academy of Sciences; Vavilova str., 28 119991 Moscow Russia
| | - Ivan V. Ananyev
- A. N. Nesmeyanov Institute of Organoelement Compounds; Russian Academy of Sciences; Vavilova str., 28 119991 Moscow Russia
| | - Nina N. Makhova
- N.D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prospect, 47 119991 Moscow Russia
| |
Collapse
|
22
|
Vairoletti F, Medeiros A, Fontán P, Meléndrez J, Tabárez C, Salinas G, Franco J, Comini MA, Saldaña J, Jancik V, Mahler G, Saiz C. Synthesis of bicyclic 1,4-thiazepines as novel anti- Trypanosoma brucei brucei agents. MEDCHEMCOMM 2019; 10:1481-1487. [PMID: 31673311 DOI: 10.1039/c9md00064j] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 06/09/2019] [Indexed: 11/21/2022]
Abstract
1,4-Thiazepines derivatives are pharmacologically important heterocycles with different applications in medicinal chemistry. In the present work, we describe the preparation of new bicyclic thiazolidinyl-1,4-thiazepines 3 by reaction between azadithiane compounds and Michael acceptors. The reaction scope was explored and the yields were optimized. The activity of the new compounds was evaluated against Nippostrongylus brasiliensis and Caenorhabditis elegans as anthelmintic models and Trypanosoma brucei brucei. The most active compound was 3l, showing an EC50 = 2.8 ± 0.7 μM against T. b. brucei and a selectivity index >71.
Collapse
Affiliation(s)
- Franco Vairoletti
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| | - Andrea Medeiros
- Group Redox Biology of Trypanosomes , Institut Pasteur de Montevideo , Montevideo , Uruguay.,Departamento de Bioquímica , Facultad de Medicina , Universidad de la República , Montevideo , Uruguay
| | - Pablo Fontán
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| | - Jennifer Meléndrez
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| | - Carlos Tabárez
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| | - Gustavo Salinas
- Worm Biology Laboratory , Unidad Mixta Institut Pasteur de Montevideo-Facultad de Química , UdelaR , Montevideo , Uruguay
| | - Jaime Franco
- Group Redox Biology of Trypanosomes , Institut Pasteur de Montevideo , Montevideo , Uruguay
| | - Marcelo A Comini
- Group Redox Biology of Trypanosomes , Institut Pasteur de Montevideo , Montevideo , Uruguay
| | - Jenny Saldaña
- Laboratorio de Experimentación Animal , Depto de Ciencias Farmacéuticas , Facultad de Química , Universidad de la República , Montevideo , Uruguay
| | - Vojtech Jancik
- Centro Conjunto de Investigación en Química Sustentable UAEM-UNAM , Toluca , Mexico
| | - Graciela Mahler
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| | - Cecilia Saiz
- Laboratorio de Química Farmacéutica , Departamento de Química Orgánica , Facultad de Química , Universidad de la República , Montevideo , Uruguay . ;
| |
Collapse
|
23
|
Herrera-Mayorga V, Lara-Ramírez EE, Chacón-Vargas KF, Aguirre-Alvarado C, Rodríguez-Páez L, Alcántara-Farfán V, Cordero-Martínez J, Nogueda-Torres B, Reyes-Espinosa F, Bocanegra-García V, Rivera G. Structure-Based Virtual Screening and In Vitro Evaluation of New Trypanosoma cruzi Cruzain Inhibitors. Int J Mol Sci 2019; 20:ijms20071742. [PMID: 30970549 PMCID: PMC6479639 DOI: 10.3390/ijms20071742] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 04/05/2019] [Accepted: 04/05/2019] [Indexed: 11/16/2022] Open
Abstract
Chagas disease (CD), or American trypanosomiasis, causes more than 10,000 deaths per year in the Americas. Current medical therapy for CD has low efficacy in the chronic phase of the disease and serious adverse effects; therefore, it is necessary to search for new pharmacological treatments. In this work, the ZINC15 database was filtered using the N-acylhydrazone moiety and a subsequent structure-based virtual screening was performed using the cruzain enzyme of Trypanosoma cruzi to predict new potential cruzain inhibitors. After a rational selection process, four compounds, Z2 (ZINC9873043), Z3 (ZINC9870651), Z5 (ZINC9715287), and Z6 (ZINC9861447), were chosen to evaluate their in vitro trypanocidal activity and enzyme inhibition. Compound Z5 showed the best trypanocidal activity against epimatigote (IC50 = 36.26 ± 9.9 μM) and trypomastigote (IC50 = 166.21 ± 14.5 μM and 185.1 ± 8.5 μM on NINOA and INC-5 strains, respectively) forms of Trypanosoma cruzi. In addition, Z5 showed a better inhibitory effect on Trypanosoma cruzi proteases than S1 (STK552090, 8-chloro-N-(3-morpholinopropyl)-5H-pyrimido[5,4-b]-indol-4-amine), a known cruzain inhibitor. This study encourages the use of computational tools for the rational search for trypanocidal drugs.
Collapse
Affiliation(s)
- Verónica Herrera-Mayorga
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
- Departamento de Ingeniería Bioquímica, Unidad Académica Multidisciplinaria Mante, Universidad Autónoma de Tamaulipas, Mante 89840, Mexico.
| | - Edgar E Lara-Ramírez
- Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social (IMSS), Zacatecas 98000, Mexico.
| | - Karla F Chacón-Vargas
- Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Ciudad de México 11340, Mexico.
| | - Charmina Aguirre-Alvarado
- Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
- Unidad de Investigación en Infectología e Inmunología, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México 029990, Mexico.
| | - Lorena Rodríguez-Páez
- Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
| | - Verónica Alcántara-Farfán
- Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
| | - Joaquín Cordero-Martínez
- Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
| | - Benjamín Nogueda-Torres
- Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Ciudad de México 11340, Mexico.
| | - Francisco Reyes-Espinosa
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
| | - Virgilio Bocanegra-García
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
| | - Gildardo Rivera
- Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
| |
Collapse
|
24
|
Herrera Acevedo C, Scotti L, Alves MF, de F.F.M. Diniz M, Tullius Scotti M. Hybrid Compounds in the Search for Alternative Chemotherapeutic Agents against Neglected Tropical Diseases. LETT ORG CHEM 2019. [DOI: 10.2174/1570178615666180402123057] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Neglected tropical diseases (NTDs) affect more than a billion people worldwide, mainly
populations living in poverty conditions. More than 56% of annual NTD deaths are caused by
Leishmaniasis, Sleeping sickness, and Chagas disease. For these three diseases, many problems have
been observed with the chemotherapeutic drugs commonly used, these being mainly resistance, high
toxicity, and low efficacy. In the search for alternative treatments, hybridization is an interesting approach,
which generates new molecules by merging two pharmacophores and then looking for improvements
in biological activity or reduced compound toxicity. Here, we review various studies that
present such hybrid molecules with promising in vitro and in vivo activities against Leishmania and
Trypanosoma parasites.
Collapse
Affiliation(s)
- Chonny Herrera Acevedo
- Post-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, 58051-900 Joao Pessoa, PB, Brazil
| | - Luciana Scotti
- Post-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, 58051-900 Joao Pessoa, PB, Brazil
| | - Mateus F. Alves
- Post-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, 58051-900 Joao Pessoa, PB, Brazil
| | - Margareth de F.F.M. Diniz
- Post-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, 58051-900 Joao Pessoa, PB, Brazil
| | - Marcus Tullius Scotti
- Post-Graduate Program in Natural and Synthetic Bioactive Products, Federal University of Paraiba, 58051-900 Joao Pessoa, PB, Brazil
| |
Collapse
|
25
|
Costa RA, Cruz JN, Nascimento FCA, Silva SG, Silva SO, Martelli MC, Carvalho SML, Santos CBR, Neto AMJC, Brasil DSB. Studies of NMR, molecular docking, and molecular dynamics simulation of new promising inhibitors of cruzaine from the parasite Trypanosoma cruzi. Med Chem Res 2018. [DOI: 10.1007/s00044-018-2280-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
26
|
Mir BA, Singh SJ, Kumar R, Patel BK. tert-
Butyl Nitrite Mediated Different Functionalizations of Internal Alkenes: Paths to Furoxans and Nitroalkenes. Adv Synth Catal 2018. [DOI: 10.1002/adsc.201800668] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Bilal Ahmad Mir
- Department of Chemistry; Indian Institute of Technology Guwahati, North Guwahati; 781 039 Assam India
| | | | - Ritush Kumar
- Department of Chemistry; Indian Institute of Technology Guwahati, North Guwahati; 781 039 Assam India
| | - Bhisma K. Patel
- Department of Chemistry; Indian Institute of Technology Guwahati, North Guwahati; 781 039 Assam India
| |
Collapse
|
27
|
Yépes AF, Bahsas A, Escobar P, Cobo J, Palma A, Garro Martinez JC, Enriz R. Synthesis, anti-parasitic activity and QSAR study of a new library of polysubstituted tetrahydronaphtho[1,2-b]azepines. Med Chem Res 2018. [DOI: 10.1007/s00044-018-2232-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
28
|
Chen J, Li X, Li J, Li J, Huang L, Ren T, Yang X, Zhong S. Assembling of stimuli-responsive tumor targeting polypyrrole nanotubes drug carrier system for controlled release. MATERIALS SCIENCE & ENGINEERING. C, MATERIALS FOR BIOLOGICAL APPLICATIONS 2018; 89:316-327. [DOI: 10.1016/j.msec.2018.04.031] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 03/03/2018] [Accepted: 04/12/2018] [Indexed: 11/29/2022]
|
29
|
Ingold M, Dapueto R, Victoria S, Galliusi G, Batthyàny C, Bollati-Fogolín M, Tejedor D, García-Tellado F, Padrón JM, Porcal W, López GV. A green multicomponent synthesis of tocopherol analogues with antiproliferative activities. Eur J Med Chem 2018; 143:1888-1902. [DOI: 10.1016/j.ejmech.2017.11.003] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 10/31/2017] [Accepted: 11/01/2017] [Indexed: 11/16/2022]
|
30
|
Vergara S, Carda M, Agut R, Yepes LM, Vélez ID, Robledo SM, Galeano WC. Synthesis, antiprotozoal activity and cytotoxicity in U-937 macrophages of triclosan–hydrazone hybrids. Med Chem Res 2017. [DOI: 10.1007/s00044-017-2019-2] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
31
|
Serafim RAM, Pernichelle FG, Ferreira EI. The latest advances in the discovery of nitric oxide hybrid drug compounds. Expert Opin Drug Discov 2017; 12:941-953. [PMID: 28664751 DOI: 10.1080/17460441.2017.1344400] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
INTRODUCTION There is a great interest in Nitric oxide (NO) within medicinal chemistry since it's involved in human signaling pathways. Prodrugs or hybrid compounds containing NO-donor scaffolds linked to an active compound are valuable, due to their potential for modulating many pathological conditions due to NO's biological properties when released in addition to the native drug. Compounds that selectively inhibit nitric oxide synthase isoforms (NOS) can also increase therapeutic capacity, particularly in the treatment of chronic diseases. However, search for bioactive compounds to efficiently and selectively modulate NO is still a challenge in drug discovery. Areas covered: In this review, the authors highlight the recent advances in the strategies used to discover NO-hybrid derivatives, especially those related to anti-inflammatory, cardiovascular, anticancer and anti-microorganism activities. They also focus on: nitric oxide synthase inhibitors, NO delivery materials and other related activities. Expert opinion: The process of molecular hybridization can be used to obtain NO-releasing compounds that also interact with different targets. The main problem with this approach is to control NO multiple actions in the right biological system. However, the use of NO-releasing groups with many different scaffolds leads to new molecular structures for bioactive compounds, suggesting synergies.
Collapse
Affiliation(s)
- Ricardo A M Serafim
- a LAPEN: Laboratory of Design and Synthesis of Chemotherapeutic Potentially Active against Neglected Diseases, Department of Pharmacy, Faculty of Pharmaceutical Sciences , University of São Paulo - FCF/USP , São Paulo , Brazil
| | - Filipe G Pernichelle
- a LAPEN: Laboratory of Design and Synthesis of Chemotherapeutic Potentially Active against Neglected Diseases, Department of Pharmacy, Faculty of Pharmaceutical Sciences , University of São Paulo - FCF/USP , São Paulo , Brazil
| | - Elizabeth I Ferreira
- a LAPEN: Laboratory of Design and Synthesis of Chemotherapeutic Potentially Active against Neglected Diseases, Department of Pharmacy, Faculty of Pharmaceutical Sciences , University of São Paulo - FCF/USP , São Paulo , Brazil
| |
Collapse
|
32
|
Fershtat LL, Makhova NN. Molecular Hybridization Tools in the Development of Furoxan-Based NO-Donor Prodrugs. ChemMedChem 2017; 12:622-638. [DOI: 10.1002/cmdc.201700113] [Citation(s) in RCA: 61] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Revised: 03/27/2017] [Indexed: 11/08/2022]
Affiliation(s)
- Leonid L. Fershtat
- N. D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prosp. 47 Moscow 119991 Russian Federation
| | - Nina N. Makhova
- N. D. Zelinsky Institute of Organic Chemistry; Russian Academy of Sciences; Leninsky Prosp. 47 Moscow 119991 Russian Federation
| |
Collapse
|
33
|
Bittencourt IDA, Serpeloni M, Hiraiwa PM, de Arruda Campos Brasil de Souza T, Ávila AR. Dissecting biochemical peculiarities of the ATPase activity of TcSub2, a component of the mRNA export pathway in Trypanosoma cruzi. Int J Biol Macromol 2017; 98:793-801. [PMID: 28212935 DOI: 10.1016/j.ijbiomac.2017.02.050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 02/10/2017] [Accepted: 02/11/2017] [Indexed: 11/16/2022]
Abstract
The RNA helicase DEAD-box protein Sub2 (yeast)/UAP56 (mammals) is conserved across eukaryotes and is essential for mRNA export in trypanosomes. Despite the high conservation of Sub2 in lower eukaryotes such as Trypanosoma cruzi, the low conservation of other mRNA export factors raises questions regarding whether the mode of action of TcSub2 is similar to that of orthologs from other eukaryotes. Mutation of the conserved K87 residue of TcSub2 abolishes ATPase activity, showing that its ATPase domain is functional. However, the Vmax of TcSub2 was much higher than the Vmax described for the human protein UAP56, which suggests that the TcSub2 enzyme hydrolyzes ATP faster than its human homolog. Furthermore, we demonstrate that RNA association is less important to the activity of TcSub2 compared to UAP56. Our results show differences in activity of this protein, even though the structure of TcSub2 is very similar to UAP56. Functional complementation assays indicate that these differences may be common to other trypanosomatids. Distinct features of RNA influence and ATPase efficiency between UAP56 and TcSub2 may reflect distinct structures for functional sites of TcSub2. For this reason, ligand-based or structure-based methodologies can be applied to investigate the potential of TcSub2 as a target for new drugs.
Collapse
|
34
|
Serafim RAM, de Oliveira TF, Loureiro APM, Krogh R, Andricopulo AD, Dias LC, Ferreira EI. Molecular modeling and structure–activity relationships studies of bioisoster hybrids of N-acylhydrazone and furoxan groups on cruzain. Med Chem Res 2017. [DOI: 10.1007/s00044-016-1776-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
35
|
Segretti ND, Serafim RA, Segretti MC, Miyata M, Coelho FR, Augusto O, Ferreira EI. New antibacterial agents: Hybrid bioisoster derivatives as potential E. coli FabH inhibitors. Bioorg Med Chem Lett 2016; 26:3988-93. [DOI: 10.1016/j.bmcl.2016.06.089] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 06/28/2016] [Accepted: 06/29/2016] [Indexed: 11/30/2022]
|
36
|
Fernandes GFDS, de Souza PC, Marino LB, Chegaev K, Guglielmo S, Lazzarato L, Fruttero R, Chung MC, Pavan FR, Dos Santos JL. Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. Eur J Med Chem 2016; 123:523-531. [PMID: 27508879 DOI: 10.1016/j.ejmech.2016.07.039] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2016] [Revised: 06/16/2016] [Accepted: 07/19/2016] [Indexed: 12/21/2022]
Abstract
Tuberculosis (TB) remains a serious health problem responsible to cause millions of deaths annually. The scenario becomes alarming when it is evaluated that the number of new drugs does not increase proportionally to the emergence of resistance to the current therapy. Furoxan derivatives, known as nitric oxide (NO) donors, have been described to exhibit antitubercular activity. Herein, a novel series of hybrid furoxan derivatives (1,2,5-oxadiazole 2-N-oxide) (compounds 4a-c, 8a-c and 14a-c) were designed, synthesized and evaluated in vitro against Mycobacterium tuberculosis (MTB) H37Rv (ATCC 27294) and a clinical isolate MDR-TB strain. The furoxan derivatives have exhibited MIC90 values ranging from 1.03 to 62 μM (H37Rv) and 7.0-50.0 μM (MDR-TB). For the most active compounds (8c, 14a, 14b and 14c) the selectivity index ranged from 3.78 to 52.74 (MRC-5 cells) and 1.25-34.78 (J774A.1 cells). In addition, it was characterized for those compounds logPo/w values between 2.1 and 2.9. All compounds were able to release NO at levels ranging from 0.16 to 44.23%. Among the series, the phenylsulfonyl furoxan derivatives (compounds 14a-c) were the best NO-donor with the lowest MIC90 values. The most active compound (14c) was also stable at different pHs (5.0 and 7.4). In conclusion, furoxan derivatives were identified as new promising compounds useful to treat tuberculosis.
Collapse
Affiliation(s)
| | - Paula Carolina de Souza
- School of Pharmaceutical Sciences, UNESP - Univ Estadual Paulista, Araraquara, 14800903, Brazil
| | | | - Konstantin Chegaev
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Turin, 10124, Italy
| | - Stefano Guglielmo
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Turin, 10124, Italy
| | - Loretta Lazzarato
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Turin, 10124, Italy
| | - Roberta Fruttero
- Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Turin, 10124, Italy
| | - Man Chin Chung
- School of Pharmaceutical Sciences, UNESP - Univ Estadual Paulista, Araraquara, 14800903, Brazil
| | - Fernando Rogério Pavan
- School of Pharmaceutical Sciences, UNESP - Univ Estadual Paulista, Araraquara, 14800903, Brazil
| | - Jean Leandro Dos Santos
- School of Pharmaceutical Sciences, UNESP - Univ Estadual Paulista, Araraquara, 14800903, Brazil.
| |
Collapse
|
37
|
Silva-Júnior EF, Silva EPS, França PHB, Silva JPN, Barreto EO, Silva EB, Ferreira RS, Gatto CC, Moreira DRM, Siqueira-Neto JL, Mendonça-Júnior FJB, Lima MCA, Bortoluzzi JH, Scotti MT, Scotti L, Meneghetti MR, Aquino TM, Araújo-Júnior JX. Design, synthesis, molecular docking and biological evaluation of thiophen-2-iminothiazolidine derivatives for use against Trypanosoma cruzi. Bioorg Med Chem 2016; 24:4228-4240. [PMID: 27475533 DOI: 10.1016/j.bmc.2016.07.013] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2016] [Revised: 07/06/2016] [Accepted: 07/08/2016] [Indexed: 01/17/2023]
Abstract
In this study, we designed and synthesized a series of thiophen-2-iminothiazolidine derivatives from thiophen-2-thioureic with good anti-Trypanosoma cruzi activity. Several of the final compounds displayed remarkable trypanocidal activity. The ability of the new compounds to inhibit the activity of the enzyme cruzain, the major cysteine protease of T. cruzi, was also explored. The compounds 3b, 4b, 8b and 8c were the most active derivatives against amastigote form, with significant IC50 values between 9.7 and 6.03μM. The 8c derivative showed the highest potency against cruzain (IC50=2.4μM). Molecular docking study showed that this compound can interact with subsites S1 and S2 simultaneously, and the negative values for the theoretical energy binding (Eb=-7.39kcal·mol(-1)) indicates interaction (via dipole-dipole) between the hybridized sulfur sp(3) atom at the thiazolidine ring and Gly66. Finally, the results suggest that the thiophen-2-iminothiazolidines synthesized are important lead compounds for the continuing battle against Chagas disease.
Collapse
Affiliation(s)
- E F Silva-Júnior
- Medicinal Chemistry Laboratory, Pharmacy and Nursing School, Federal University of Alagoas, Maceio, Brazil
| | - E P S Silva
- Medicinal Chemistry Laboratory, Pharmacy and Nursing School, Federal University of Alagoas, Maceio, Brazil
| | - P H B França
- Medicinal Chemistry Laboratory, Pharmacy and Nursing School, Federal University of Alagoas, Maceio, Brazil
| | - J P N Silva
- Cell Biology Laboratory, Federal University of Alagoas, Maceio, Brazil
| | - E O Barreto
- Cell Biology Laboratory, Federal University of Alagoas, Maceio, Brazil
| | - E B Silva
- Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - R S Ferreira
- Biochemistry and Immunology Department, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, Brazil
| | - C C Gatto
- Inorganic Synthesis and Crystallography Laboratory, Institute of Chemistry, University of Brasilia, Federal District, Brazil
| | - D R M Moreira
- Tissue Engineering and Immunopharmacology Laboratory, Oswaldo Cruz Foundation, Salvador, Bahia, Brazil
| | - J L Siqueira-Neto
- Skaggs School of Pharmacy and Pharmaceutical Sciences, California, San Diego La Jolla, United States
| | - F J B Mendonça-Júnior
- Laboratory of Drug Synthesis and Delivery, Biological Sciences Department, State University of Paraiba, Campus V, João Pessoa, Brazil
| | - M C A Lima
- Drug Design and Synthesis Laboratory, National Science and Technology Institute for Pharmaceutical Innovation, Federal University of Pernambuco, Recife, Brazil
| | - J H Bortoluzzi
- Catalysis and Chemical Reactivity Group (GCaR), Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceio, Brazil
| | - M T Scotti
- Laboratory of Drug Synthesis and Delivery, Biological Sciences Department, State University of Paraiba, Campus V, João Pessoa, Brazil
| | - L Scotti
- Laboratory of Drug Synthesis and Delivery, Biological Sciences Department, State University of Paraiba, Campus V, João Pessoa, Brazil
| | - M R Meneghetti
- Catalysis and Chemical Reactivity Group (GCaR), Institute of Chemistry and Biotechnology, Federal University of Alagoas, Maceio, Brazil
| | - T M Aquino
- Medicinal Chemistry Laboratory, Pharmacy and Nursing School, Federal University of Alagoas, Maceio, Brazil.
| | - J X Araújo-Júnior
- Medicinal Chemistry Laboratory, Pharmacy and Nursing School, Federal University of Alagoas, Maceio, Brazil
| |
Collapse
|
38
|
Bermudez J, Davies C, Simonazzi A, Pablo Real J, Palma S. Current drug therapy and pharmaceutical challenges for Chagas disease. Acta Trop 2016; 156:1-16. [PMID: 26747009 DOI: 10.1016/j.actatropica.2015.12.017] [Citation(s) in RCA: 158] [Impact Index Per Article: 19.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 12/23/2015] [Accepted: 12/25/2015] [Indexed: 12/11/2022]
Abstract
One of the most significant health problems in the American continent in terms of human health, and socioeconomic impact is Chagas disease, caused by the protozoan parasite Trypanosoma cruzi. Infection was originally transmitted by reduviid insects, congenitally from mother to fetus, and by oral ingestion in sylvatic/rural environments, but blood transfusions, organ transplants, laboratory accidents, and sharing of contaminated syringes also contribute to modern day transmission. Likewise, Chagas disease used to be endemic from Northern Mexico to Argentina, but migrations have earned it global. The parasite has a complex life cycle, infecting different species, and invading a variety of cells - including muscle and nerve cells of the heart and gastrointestinal tract - in the mammalian host. Human infection outcome is a potentially fatal cardiomyopathy, and gastrointestinal tract lesions. In absence of a vaccine, vector control and treatment of patients are the only tools to control the disease. Unfortunately, the only drugs now available for Chagas' disease, Nifurtimox and Benznidazole, are relatively toxic for adult patients, and require prolonged administration. Benznidazole is the first choice for Chagas disease treatment due to its lower side effects than Nifurtimox. However, different strategies are being sought to overcome Benznidazole's toxicity including shorter or intermittent administration schedules-either alone or in combination with other drugs. In addition, a long list of compounds has shown trypanocidal activity, ranging from natural products to specially designed molecules, re-purposing drugs commercialized to treat other maladies, and homeopathy. In the present review, we will briefly summarize the upturns of current treatment of Chagas disease, discuss the increment on research and scientific publications about this topic, and give an overview of the state-of-the-art research aiming to produce an alternative medication to treat T. cruzi infection.
Collapse
|
39
|
Leverrier A, Bero J, Cabrera J, Frédérich M, Quetin-Leclercq J, Palermo JA. Structure-activity relationship of hybrids of Cinchona alkaloids and bile acids with in vitro antiplasmodial and antitrypanosomal activities. Eur J Med Chem 2015; 100:10-7. [DOI: 10.1016/j.ejmech.2015.05.044] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Revised: 05/29/2015] [Accepted: 05/30/2015] [Indexed: 01/26/2023]
|